Sign up
Pharma Capital

Horizon Discovery Group inks 'significant' reference standards deal

Chris Claxton, Vice President of Investor Relations and Corporate Communications at Horizon Discovery Group PLC (LON:HZD) talks to Proactive about the company entering into an agreement with an unnamed global molecular diagnostics provider to develop reference standards for non-invasive prenatal testing (NIPT).


View full HZD profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.